Skip to main content
Equibles
KLRS logo

KLRS · Kalaris Therapeutics, Inc.

Track KLRS — free

Use KLRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KLRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.26 -0.10 (-4.24%) At close · Oct 12
Rebalance outlook locked
Market Cap
$56.18M
Shares
23.80M
Volume · Oct 12 122.09K Avg daily vol (3M) 250.65K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.36 Open$2.46 Day$2.36–2.55 52W close$2.36–10.98 Avg vol 30d75K Short int332K · 1.4% float · 4.6d Short vol3% Last earningsFeb 15, 2023 DataJul 2020–Oct 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$44.26M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-16,182.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$93.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.2%
Year over year · more shares
Price change (1Y)
-49.0%
Trailing year
Short interest
1.4%
Latest settlement · 4.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −60%
below
Price vs 50-day avg −33%
below
RSI (14) 20
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −30%
trailing
6-month return −64%
trailing
YTD return −72%
this year
Relative strength −74%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.39% of float · ▲ +4.2% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — mid 1-yr range
Squeeze score 39
low risk · 0–100
Fundamentals
Fair
EPS growth +94%
Y/Y
Free cash flow $-38.6M
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −79%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−60% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
20 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.39% of float · ▲ +4.2% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $11
vs 200-day avg -60% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KLRS
Kalaris Therapeutics, Inc.
this stock
$56.18M -72.0% — — 1.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.77B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
56
% held
75.7%
Net QoQ
-547.8K sh
Top holder
SAMSARA BIOCAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
20
View
Short & Settlement
Short Interest Rising
Shares short
331.9K
Days to cover
4.6d
Change
+13.5K sh
View
Short Volume
Short vol %
3%
As of
Oct 12, 2026
Short Total
View
Fails to Deliver
FTD shares
11
Value
$37
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
34.1%
Week of
Sep 7, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$165.0K
Net income (FY)
$-43.4M
EPS diluted
$-2.85
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
13
View
Proposed Sales
Value
$12.9K
Shares
1.9K
Filed
Mar 20, 2026
View
Earnings & Events
Webcasts
Last webcast
Feb 15, 2023
View

Performance

5D 20D 120D MTD YTD
KLRS -12.6% -30.2% -64.2% -18.3% -72.0%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -13.8% -32.1% -74.1% -20.4% -86.2%
Key facts CIK 1754068 CUSIP 482929106 13F (30d) 1 filings 1 filers Visit website Investor relations